Efforts to Develop KRAS Inhibitors

Area of Science:

• Oncology
• Drug Discovery
• Molecular Biology

Background:

• KRAS mutations are prevalent in human cancers, driving significant unmet medical needs.
• Targeting oncogenic KRAS proteins with small molecules has historically proven difficult, leading to the 'undruggable' classification.
• Decades of research have yielded limited success in developing effective KRAS inhibitors.

Purpose of the Study:

• To review historical attempts at developing RAS (Rat Sarcoma virus) pathway inhibitors.
• To highlight recent advancements and promising strategies for targeting KRAS.
• To re-evaluate the feasibility of targeting KRAS in cancer therapy.

Main Methods:

• In silico screening
• Fragment-based drug design
• Disulfide tethered screening
• Exploration of emerging RAS biology themes

Main Results:

• Despite historical challenges, recent technological and biological insights are revitalizing efforts.
• New approaches are demonstrating potential for identifying novel KRAS inhibitors.
• The field is reconsidering KRAS as a druggable target.

Conclusions:

• Recent progress in drug discovery technologies and understanding of RAS biology offers renewed optimism for targeting KRAS.
• Emerging strategies show promise in overcoming previous hurdles in developing effective KRAS inhibitors for cancer treatment.